slide1
Download
Skip this Video
Download Presentation
Cannon CP et al. Crit Path Cardiol 2002;1:44-52.

Loading in 2 Seconds...

play fullscreen
1 / 16

Cannon CP et al. Crit Path Cardiol 2002;1:44-52. - PowerPoint PPT Presentation


  • 153 Views
  • Uploaded on

Underutilization of evidence-based medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Cannon CP et al. Crit Path Cardiol 2002;1:44-52.' - ouida


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Underutilization of evidence-based medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry

Christopher P. Cannon, MD * , Maria Cecilia Bahit, MD *, J. Mark Haugland §, MD , Timothy D. Henry †, MD, Marc J. Schweiger ‡, MD, George R. McKendall ¥, MD, Prediman K. Shah **, MD, Sabina Murphy ***,MPH, C.Michael Gibson***, Carolyn H. McCabe*, BS. Elliott M. Antman *, MD, Eugene Braunwald *, MD, for the TIMI 9 Registry Investigators

Cannon CP et al. Crit Path Cardiol 2002;1:44-52.

background
Background
  • Reperfusion therapy with fibrinolysis or primary angioplasty has proven to be a major advance in the treatment of acute myocardial infarction.
  • However,reports from studies in the 1980\'s and recent reports based on data from national registries have suggested that only one third of patients with acute MI receive thrombolytic therapy in North America.
background1
Background
  • Fibrinolytic therapy is beneficial only in patients with ST segment elevation (or new left bundle branch block) presenting <12 hours, and is potentially harmful in patients without ST elevation .
  • It is unclear what proportion of patientswith indications for reperfusion therapy are receiving thrombolytic therapy or primary percutaneous coronary intervention (PCI). In addition, the management and outcome of patients not treated with reperfusion therapy is poorly characterized.
objectives
Objectives
  • Assess management strategies and the outcomes of patients with acute MI presenting with ST elevation myocardial infarction (STEMI) in the current era of aggressive reperfusion therapy.
methods
Methods
  • All consecutive patients seen in the E.D and/ or admitted with the diagnosis of acute MI were prospectively screened.
  • Inclusion criteria:
    • ST elevation  0.1 mV in 2 or more leads
    • New or presumably new LBBB
  • Exclusion criteria:
    • None
  • Patient demgraphics, medical treatment , in-hospital outcome prospectively collected
results
Results

TIMI 9 Registry

n=840 consecutive

patients acute STEMI/ LBBB

20 Hospitals in US and Canada

1994

Primary PCI

n=76

No Reperfusion

n=276

Fibrinolysis

n=505

51%

TIMI 9 Trial

initial treatment strategy in stemi
Initial treatment strategy in STEMI

All patients Patients presenting < 12 hours

No Reperfusion

31%

No Reperfusion

25%

Primary

PCI

10%

Primary

PCI

9%

Fibrinolysis

60%

Fibrinolysis

65%

baseline characteristics
Baseline Characteristics

All Patients Fibrinolysis Primary PCI No Reperfusion p-value

Age 63.413.9 61.9 12.6 61.211.5 67.0 13.9 0.0001

Female 33% 30% 24% 42% 0.001

White 86% 87% 85% 86% 0.38

Prior MI 26% 17% 21% 26% 0.12

Prior

angina 27% 26% 30% 28% 0.73

Prior PCI 7% 6% 19% 7% 0.001

Prior

CABG 7% 7% 5% 7% 0.80

Prior CHF 6% 3% 4% 13% 0.001

Killip

I 80% 83% 81% 71%

II 15% 13% 12% 19%

III 4% 3% 0% 6%

IV 2% 1% 7% 3% 0.001

slide9

Door- to-drug times for patients

treated with fibrinolytic therapy

% of Patients

slide10

Door- to- balloon times for patients

treated with Primary PTCA

% of Patients

contraindications to fibrinolysis
“Contraindications” to Fibrinolysis

Fibrinolysis Prim. PCI No Reperf

Prior stroke/TIA 0.6% 2.6% 4.6%

Recent CPR,

trauma or surgery 0.8% 15.2% 12.7%

Recent Bleeding 0.2% 3.8% 10.4%

Persistent HTN 6.0% 13.9% 8.1%

Significant illness 10.3% 39.5% 42.1%

medications in 1st 24 hours
Medications in 1st 24 hours

Overall Fibrinolysis Primary PCI No Reperfusion p

Aspirin 87% 93% 93% 72% 0.001

Heparin 91% 98% 100% 74% 0.001

Beta

blockers 61% 71% 57% 43% 0.001

ACE-I 13% 13% 7% 14% 0.22

Calcium

Channel

Blockers 13% 10% 18% 17% 0.003

slide14

In-Hospital Mortality

%

3 way p<0.001

% of Patients

%

%

n= 79

n=259

n=505

in hospital outcomes
In-hospital outcomes

Overall Lysis 1o PCI No Rep.Rx p

Re-MI 8.1% 10.4% 5.5% 4.3% 0.01

Card

shock 7.4% 5.6% 13.5% 9.3% 0.02

Mild/Mod

CHF 22.6% 20.6% 20.8% 25.1% 0.45

ICH 0.2% 0.2% 0% 0.4% 0.80

Major

Bleed 5.8% 8.3% 2.9% 1.6% 0.001

timi 9 registry conclusions
TIMI 9 Registry: Conclusions
  • Reperfusion therapy underutilized – 1/3 STEMI failed to receive reperfusion Rx
  • Door to drug and door to balloon times remain suboptimal
  • There is potential to increase the use of other effective medications (e.g., ASA, B-blockers)
  • Efforts need to continue to expand the use of guideline-recommended therapies to all appropriate STEMI patients
ad